Gene Therapy Program | University of Pennsylvania

The World News Monitor | April 08, 2020

• 3 Blue-Chip Biotech Stocks Hitting New Highs. A basket of biotech stocks have surged to new highs in recent weeks, lifting the iShares Nasdaq Biotechnology Index Fund ETF (IBB) within 15 points of 2019 resistance.The stock posted an all-time high at $128 in Tuesday’s session, lifting above 2019 resistance at $122. Price action into the second half of 2019 carved a long series of lower highs and lower lows, dropping the stock to a six-year low....

INDUSTRIAL IMPACT

Enteris BioPharma | May 04, 2021

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Lexogen | June 17, 2020

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

CELL AND GENE THERAPY

Gritstone bio | December 07, 2021

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine ...